Invitro activity of MCB3681 against clostridium difficile strains

Anaerobe

Volumn 28, Issue , 2014, Pages 216-219

  Rashid, Mamun Ur ^a   Dalhoff, Axel ^b   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Clostridium difficile infections; Invitro activity; MCB3681, MCB3837

Indexed keywords

ANTIINFECTIVE AGENT; CADAZOLID; CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; LINEZOLID; MCB 3681; METRONIDAZOLE; MOXIFLOXACIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; BACTERIAL TOXIN;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE TOXIN A GENE; CLOSTRIDIUM DIFFICILE TOXIN B GENE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG POTENCY; GENE DELETION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TCDC GENE; ADULT; AGED; CLASSIFICATION; CLOSTRIDIUM INFECTION; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RIBOTYPING; YOUNG ADULT;

EID: 84904743241     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.07.001     Document Type: Article

References (30)

1. Nord C.E., Kager L., Heimdahl A. Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med 1984, 76:99-106.
2. Thomas C., Stevenson M., Riley T.V. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. JAntimicrob Chemother 2003, 51:1339-1350.
3. Yan Q., Zhang J., Chen C., Zhou H., Du P., Cui Z., et al. Multilocus sequence typing (MLST) analysis of 104 Clostridium difficile strains isolated from China. Epidemiol Infect 2012, 1-5.
4. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. JInfect 2009, 58:403-410.
5. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
6. Cocanour C.S. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect 2011, 12:235-239.
7. Ananthakrishnan A.N. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011, 8:17-26.
8. Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., Petit J.C. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. JClin Microbiol 2000, 38:2386-2388.
9. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364:422-431.
10. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. NEngl J Med 2002, 346:334-339.
11. Petrella L.A., Sambol S.P., Cheknis A., Nagaro K., Kean Y., Sears P.S., et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C.difficile BI strain. Clin Infect Dis 2012, 55:351-357.
12. Kato H., Kato N., Watanabe K., Iwai N., Nakamura H., Yamamoto T., et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. JClin Microbiol 1998, 36:2178-2182.
13. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
14. Bauer M.P., Kuijper E.J., van Dissel J.T. European society of clinical M, infectious D. European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079.
15. Gerding D.N., Johnson S. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. Nat Rev Gastroenterol Hepatol 2011, 8:67-68.
16. Bradbury B.J., Pucci M.J. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008, 8:574-581.
17. Barbachyn M.R. Recent advances in the discovery of hybrid antibacterial agents. Annual reports in medicinal chemistry 2008, 281-290. Chapter 17, Academic Press. E.M. John (Ed.).
18. Pokrovskaya V., Baasov T. Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin Drug Discov 2010, 5:883-902.
19. Delmee M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect 2001, 7:411-416.
20. Huang H., Weintraub A., Fang H., Nord C.E. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. JClin Microbiol 2009, 47:3729-3731.
21. Stubbs S.L., Brazier J.S., O'Neill G.L., Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. JClin Microbiol 1999, 37:461-463.
22. Rashid M.U., Lozano H.M., Weintraub A., Nord C.E. Invitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 2013, 20:32-35.
23. CLSI Methods for antimicrobial susceptibility testing of anaerobic bacteria 2012, Approved Standard. 8th ed.
24. Hughes K.L. Recent knowledge of the strict anaerobes of the gut. Aust Vet J 1972, 48:508-514.
25. Rashid M.U., Dalhoff A., Backstrom T., Bjorkhem-Bergman L., Panagiotidis G., Weintraub A., et al. Ecological impact of MCB3837 on the normal human microbiota. Int J Antimicrob Agents 2014, 10.1016/j.ijantimicag.2014.03.016.
26. Keessen E.C., Hensgens M.P., Spigaglia P., Barbanti F., Sanders I.M., Kuijper E.J., et al. Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078. Antimicrob Resist Infect Control 2013, 2:14.
27. Pelaez T., Alcala L., Blanco J.L., Alvarez-Perez S., Marin M., Martin-Lopez A., et al. Characterization of swine isolates of Clostridium difficile in Spain: a potential source of epidemic multidrug resistant strains?. Anaerobe 2013, 22:45-49.
28. Akerlund T., Persson I., Unemo M., Noren T., Svenungsson B., Wullt M., et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. JClin Microbiol 2008, 46:1530-1533.
29. Debast S.B., Bauer M.P., Kuijper E.J., The C. European society of clinical microbiology and infectious diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2014, 20 Suppl. 2:1-26.
30. Crowther G.S., Baines S.D., Todhunter S.L., Freeman J., Chilton C.H., Wilcox M.H. Evaluation of NVB302 versus vancomycin activity in an invitro human gut model of Clostridium difficile infection. JAntimicrob Chemother 2013, 68:168-176.